戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 t and specific elimination of tumor cells by cellular immunotherapy.
2 f toxicities as well as other limitations of cellular immunotherapy.
3 ed to obtain sufficient numbers of cells for cellular immunotherapy.
4  detection of T cell populations relevant to cellular immunotherapy.
5 a novel approach for vaccine development and cellular immunotherapy.
6 in NPC renders it an appealing candidate for cellular immunotherapy.
7 d underscores their potential application in cellular immunotherapy.
8 h in animal models and in clinical trials of cellular immunotherapy.
9 xpansion of these cells for potential use in cellular immunotherapy.
10 imerism as a potential platform for adoptive cellular immunotherapy.
11  in the development of new forms of adoptive cellular immunotherapy.
12 ent question to address in the next stage of cellular immunotherapy.
13 nes, and are being investigated as a nascent cellular immunotherapy.
14 a more clinically actionable next-generation cellular immunotherapy.
15 ategy in enabling "off-the-shelf" allogeneic cellular immunotherapies.
16 ell (HSPC) transplantation, but also advance cellular immunotherapies.
17 eases, hematopoietic SC transplantation, and cellular immunotherapies.
18 ease models, the tumor microenvironment, and cellular immunotherapies.
19 ication in the clinical development of novel cellular immunotherapies.
20 enotype; however, it has not been applied to cellular immunotherapies.
21 ymopoiesis, and the use of adjuvant-targeted cellular immunotherapies.
22 ress, which influences delivery of drugs and cellular immunotherapies.
23  is currently being redefined by humoral and cellular immunotherapies.
24 acy of CAR T-cell therapy and other emerging cellular immunotherapies.
25 T cell dysfunction and limit the efficacy of cellular immunotherapies.
26  the control and safety profile of CAR-based cellular immunotherapies.
27 on is considered a pathway of resistance for cellular immunotherapies.
28                                     Adoptive cellular immunotherapy (ACT) is a potentially curative t
29 cancer vaccine trials, but also for adoptive cellular immunotherapy after ex vivo expansion.
30 ces in laboratory and clinical procedures in cellular immunotherapy, along with the development of po
31  (NK) cells have been extensively studied in cellular immunotherapy and were found to exert cytotoxic
32 eta signaling domains, represent a precision cellular immunotherapy approach for antigen-specific B c
33 hallenges in realizing the potential of this cellular immunotherapy approach.
34 fic signalling pathways, have been joined by cellular immunotherapies based on T cell engineering.
35 e this metabolic quiescence and thus augment cellular immunotherapy-based cancer therapy.
36 lantation and after transplantation adoptive cellular immunotherapy but may be complicated by a high
37                                         This cellular immunotherapy can modulate beta chemokine produ
38  understanding of ongoing cancer vaccine and cellular immunotherapy clinical trials.
39                           Tumor vaccines and cellular immunotherapies could synergize with checkpoint
40                       DCVAC/PCa is an active cellular immunotherapy designed to initiate an immune re
41 trategies in cytokine therapy, vaccines, and cellular immunotherapy, each of which might become viabl
42                           Tumor vaccines and cellular immunotherapies enhanced OS and PFS in NSCLC.
43                                   Allogeneic cellular immunotherapy exhibits promising efficacy for c
44 g CRISPR has sparked a transformation in the cellular immunotherapy field, resulting in a multitude o
45 l of CRISPR technology to engineer synthetic cellular immunotherapies for a wide range of human disea
46 gy and enabled new avenues for the design of cellular immunotherapies for cancer.
47 at hDRAGA mice are a valuable model to study cellular immunotherapies for HIV.
48 dbreaking insight into future development of cellular immunotherapies for HPV-associated OPC patients
49 titute a major class of current and emergent cellular immunotherapies for the treatment of disease, i
50 oundwork for future development of precision cellular immunotherapy for AChR-MG.
51 isease onset, suggesting a novel approach to cellular immunotherapy for autoimmunity.
52    Natural killer (NK) cells are a promising cellular immunotherapy for cancer.
53 uggest a potential novel approach to augment cellular immunotherapy for cancer.
54  therapies are the gold standard of adoptive cellular immunotherapy for hematopoietic malignancies.
55 ion TIL therapy as a promising and adaptable cellular immunotherapy for one of the most treatment-res
56  initial toxicity profile of a BCMA-directed cellular immunotherapy for patients with relapsed or ref
57                                              Cellular Immunotherapy for Septic Shock is the first-in-
58 HSCT) has evolved into an effective adoptive cellular immunotherapy for the treatment of a number of
59 s promising approach may be used to optimize cellular immunotherapy for treating heterogeneous solid
60 X-321 is a potential 'off-the-shelf' in vivo cellular immunotherapy for treating HPV + cancers, inclu
61 be critical in developing effective adoptive cellular immunotherapy for viral infections and cancer.
62 In addition, work on mRNA-encoded protein or cellular immunotherapies has also begun, for which minim
63 nce EBV-specific T cells could prevent PTLD, cellular immunotherapy has been a promising treatment op
64                      This innovative form of cellular immunotherapy has been associated with remarkab
65                                              Cellular immunotherapy has revolutionized the treatment
66           Sipuleucel-T, an autologous active cellular immunotherapy, has shown evidence of efficacy i
67                                   Allogeneic cellular immunotherapies hold a great promise for cancer
68                                   Allogeneic cellular immunotherapies hold promise for broad clinical
69 onments, to generate more effective adoptive cellular immunotherapies in cancer, and to direct T cell
70  a strong rationale for the investigation of cellular immunotherapy in B-cell NHL.
71      In this Review, we discuss the goals of cellular immunotherapy in cancer, key challenges facing
72 ate a self-renewing source of tumor-specific cellular immunotherapy in human participants.
73  produce tumor-specific T cells for adoptive cellular immunotherapy in melanoma patients.
74 sessed the efficacy of tumor vaccination and cellular immunotherapy in NSCLC.
75 lism and highlights the potential to enhance cellular immunotherapy in solid malignancies by preservi
76 mediated cytotoxicity in vitro, and adoptive cellular immunotherapy in vivo.
77 eptor (TCR) gene therapy is a potent form of cellular immunotherapy in which patient T cells are gene
78 tion become significantly more responsive to cellular immunotherapies including chimeric antigen rece
79 ceptor (CAR)-T cells, alternative sources of cellular immunotherapy, including CAR macrophages, are e
80                                         This cellular immunotherapy is a short-term available and bro
81                                   Allogeneic cellular immunotherapy is effective even with the use of
82                                   Autologous cellular immunotherapy is hindered by the inability to b
83 ssing the potential of CD4+ CD25+ Tregs as a cellular immunotherapy is their hypoproliferative phenot
84                                              Cellular immunotherapy may provide a strategy to overcom
85 bes future avenues for their exploitation in cellular immunotherapy of malignant blood disorders.
86 mized controlled trials (RCTs) investigating cellular immunotherapy or vaccines in NSCLC.
87 oth systemic immune responses and downstream cellular immunotherapy outcomes.
88 immune checkpoint inhibitors and advances in cellular immunotherapy, particularly chimeric antigen re
89 e has seen rapid development in the field of cellular immunotherapy, particularly in regard to chimer
90                                 This form of cellular immunotherapy presents a unique opportunity to
91 ipulation of OX40 may be useful in improving cellular immunotherapy regimes for treatment of persiste
92       Our findings may guide optimization of cellular immunotherapy strategies in MM.
93 l rationale to target them as a personalized cellular immunotherapy strategy, an especially appealing
94                                              Cellular immunotherapy such as CAR T-cell therapy has en
95 ), this tumor is an attractive candidate for cellular immunotherapy targeted against tumor-associated
96 ests this tumor can be highly susceptible to cellular immunotherapy targeted to tumor associated anti
97  al. describe the development of a potential cellular immunotherapy targeting a "public" neoantigen d
98 enrolled onto a clinical trial of autologous cellular immunotherapy targeting human epidermal growth
99 tform for expanding the therapeutic index of cellular immunotherapies that target cancer.
100                          We have developed a cellular immunotherapy that uses chimeric receptors to s
101            Despite the major improvements in cellular immunotherapy, the immunogenicity of virus-spec
102 ress in the application of novel humoral and cellular immunotherapies to children and adolescents wit
103           We propose that the application of cellular immunotherapies to coordinate the immune respon
104 , integrating localized TME remodelling with cellular immunotherapies to enhance CAR T cells and othe
105 ts, these cells have potential to be used as cellular immunotherapy to control transplant arterioscle
106                                              Cellular immunotherapy to prevent CMV disease is less to
107 uld potentially serve as target antigens for cellular immunotherapy to promote GVL activity after all
108 y and gammadelta T cell-based drug resistant cellular immunotherapy to treat GBM.
109                                     Adoptive cellular immunotherapy treats metastatic cancer by infus
110 were performed in anticipation of its use in cellular immunotherapy trials for primary malignant brai
111  novel nontoxic and efficacious paradigm for cellular immunotherapy trials in human primary malignant
112 mmunotherapy using monoclonal antibodies and cellular immunotherapy using hematopoietic cell transpla
113                                     Adoptive cellular immunotherapy utilizing tumor-reactive T cells
114                                              Cellular immunotherapy was found to be more effective th
115 d mixed chimerism as a platform for adoptive cellular immunotherapy was reliably induced.
116 Lapuleucel-T (APC8024), an autologous active cellular immunotherapy, was prepared from peripheral-blo
117 come the negative effects of trogocytosis on cellular immunotherapy, we propose innovative approaches
118                            Autologous active cellular immunotherapy with lapuleucel-T was feasible, s
119  allogeneic T cells thus represent a form of cellular immunotherapy with time-limited biologic activi
120 genetic modification of T cells has advanced cellular immunotherapies, yet the delivery of biologics

 
Page Top